Biotech’s Big Gamble Fails: Insights and Implications
Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
- Latest
- Trending
Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
Aerovate Therapeutics stock downgraded by BTIG after AV-101 trial setback; mixed analyst views and future pivotal readouts crucial for investors.
Nexalin shares are 1% shorted; 52-week range $0.25-$3.40. Market cap: $6.69M, PE ratio: -1.36, beta: 5.13. Qtr EPS: -$0.10; ROE: ...
Tempus AI sold 11M shares at $37 each, launched in 2015, focuses on medical testing, with revenue growth from $320.7M ...
Altimmune's stock has seen a strong increase in value, surpassing Eli Lilly and Novo Nordisk. However, there are risks involved.
Paradromics and Neuralink are striving to develop brain-computer interfaces, however, Paradromics' device has limited data capture capability.
Researchers have successfully developed a single-dose vaccine that prompts the production of T-cells and "memory" B cells to fight against ...
A lawsuit is underway as the misuse of #ivermectin as a COVID treatment continues. The article discusses the legal ramifications ...
Pfizer's interest in the weight loss market is uncertain due to its significant debt of over $70 billion and recent ...
Moleculin Biotech's stock has been given a "sell" rating by a firm, with a 1-year low of $4.34 and a ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.